N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Subscribe To Our Newsletter & Stay Updated
